非小细胞肺癌患者血清血管内皮生长因子受体2和内皮抑素与临床特征的相关性研究(3)
 |
| 第1页 |
参见附件(2395KB，3页)。
[6] Guan XX, Yin M, Wei QY, et al. Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy [J]. BMC Cancer,2010,(10):431-432.
[7] Dong J, Dai JC, Shu YQ, et al. Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population [J]. Carcinogenesis,2010,31(6):1080-1086.
[8] Jain L, Vargo CA, Danesi R, et al. The role of vascular endothelial growth factor (VEGF) SNPs as predictive and prognostic markers for major solid tumors [J]. Mol Cancer Ther,2009,8(9):2496-2508.
[9] Carrillo E, Caso E, Sa′nchez I, et al. Prognostic significance of the expression of vascular endothelial growth factors A, B, C and D and their receptors R1, R2 and R3 in patients with non-small cell lung cancer [J]. Cancer,2009,(4):1701-1712.
[10] Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action experimental [J]. Cell Research,2006,(312):594-607.
[11] 杨大运,齐战,平育敏.内皮抑素概论及抗癌作用[J].药学与临床研究,2007,15(3):167-169.
[12] 刘颖,周清华,陆艳蓉,等.非小细胞肺癌患者血清中内皮抑素、VEGF水平及其与临床病理生理特征的关系[J].中国肺癌杂志,2004,7(1):50-54.
[13] 张兵,徐爱晖.化疗与手术对肺癌患者血清endostatin水平影响的初步观察[J].肿瘤杂志,2006,26(6):563-565.
(收稿日期：2011-10-11)
您现在查看是摘要介绍页，详见PDF附件(2395KB，3页)。